Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
You may also be interested in...
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.